Clinical Trials in Cancer Patients

Present clinical trials in cancer focused on signaling pathway blockers or inhibitors to develop personalized cancer therapies. pharmacogenomic strategies in cancer trials should be adopted that include specific molecular targeting, cancer cell genomes, modifications of cancer signaling pathways and epigenetic mechanisms. Translational oncogenomics research expands through the application of highly sensitive and specific advanced technology, computational tools to both pharmaceutical and clinical problems. Recent clinical studies have shown that gene expression data that can be distinguish between tumor types as well as to predict outcomes. In previous studies the survival rates have been unacceptably low and prognosis has been poor in the clinical trials involving ‘inoperable’ lung cancers. Individualized cancer therapy strategies and pharmacogenomic strategies had been made to get high-throughput microarray information recorded for isolated tumor cell lines from stage I through stage III cancer patients. Gene profiling expression, proteomic, interactomic and tissue array data is essential for improving the survival rate of stage III cancer patients with novel signaling pathway inhibitors/blocker medicines. Novel translational oncogenomics also used with a view of computational models in both pharmaceutical and clinical areas. Studies of Differential Gene Expression (DFG) in cancer cell lines are required for developing new efficient cancer therapies. Human Cancer Genomes and Epigenetics (HCGE) Project aims to increase the survival rates of cancer patients treated in clinical trials by using translational oncogenomics with the novel, high-efficiency/low-cost and ultra-sensitive techniques. This project also has benefit from pharmacogenomic approaches, computer simulations, varying structures of human cancer interactomes.